Triple-Receptor Drug Retatrutide Cuts Blood Sugar and Weight in Kidney Disease Patients

Patients living with both type 2 diabetes or obesity and chronic kidney disease (CKD) represent one of the most difficult-to-treat populations in metabolic medicine. CKD limits many existing pharmacological options, and achieving meaningful glycemic and weight control while protecting residual kidney function remains a pressing unmet need. Retatrutide, a first-in-class triple agonist of GIP, GLP-1, and glucagon receptors, has emerged as a potentially transformative agent, but its specific performance in this comorbid group had not been systematically quantified.

This systematic review and meta-analysis, published in Mædica (December 2025), searched major databases for randomized controlled trials investigating retatrutide in adults with diabetes and/or obesity comorbid with CKD. Eight studies met inclusion criteria. Primary endpoints were changes in HbA1c and body weight; safety was assessed through adverse event reporting. The review followed standard meta-analytic methodology with subgroup analyses stratified by dose.

The pooled results were clinically meaningful. Retatrutide produced a statistically significant mean HbA1c reduction of -1.04% (95% CI: -1.42 to -0.67), alongside substantial body weight reductions reaching up to -24.2% from baseline. These figures compare favorably to most existing approved agents for this population. A surprising dose-response pattern emerged: lower doses (≤8 mg) delivered greater HbA1c reductions (-1.39%) than higher doses (≥12 mg, -0.65%), which may reflect differential receptor engagement or titration dynamics in renally impaired patients requiring further investigation.

Perhaps equally important for this population, secondary analyses pointed toward renoprotective effects, with retatrutide treatment associated with reductions in albuminuria — a validated surrogate marker for CKD progression. If confirmed in dedicated renal outcomes trials, this could position retatrutide alongside SGLT2 inhibitors and finerenone as agents offering dual metabolic and nephroprotective benefits. The safety profile was dominated by gastrointestinal adverse events (nausea, vomiting, diarrhea), consistent with the GLP-1 receptor agonist class, and was generally manageable.

The authors conclude that retatrutide shows strong efficacy for glucose and weight management in patients with diabetes, obesity, and CKD, with a distinctive dose-response relationship and promising but preliminary kidney-protective signals. Larger, longer-term trials with hard renal endpoints are needed to fully characterize its role in this population.